Literature DB >> 22917103

Entamoeba histolytica infection in men who have sex with men.

Chien-Ching Hung1, Sui-Yuan Chang, Dar-Der Ji.   

Abstract

Entamoeba histolytica infection (amoebiasis) is the second leading cause of death from parasitic diseases. Epidemiological studies from developed countries have reported an increasing prevalence of amoebiasis and of invasive infections, such as amoebic colitis, among men who have sex with men (MSM) who engage in oral-anal sex. Although most infections with E histolytica are asymptomatic, clinical manifestations of invasive amoebiasis mainly include amoebic colitis and amoebic liver abscess, which are associated with substantial morbidity and medical cost. Laboratory diagnosis of amoebiasis should be based on detection of E histolytica by use of tests with high sensitivity and specificity, such as specific amoebic-antigen or PCR-based assays. Microscopy used in routine clinical laboratories is not sensitive or specific enough for detection of E histolytica. Metronidazole or tinidazole remains the mainstay of treatment for invasive amoebiasis, followed by treatment with luminal agents to prevent relapse and transmission of E histolytica to sexual partners or close contacts.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917103     DOI: 10.1016/S1473-3099(12)70147-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  40 in total

Review 1.  Invasive amoebiasis: a review of Entamoeba infections highlighted with case reports.

Authors:  Christopher Skappak; Sarah Akierman; Sara Belga; Kerri Novak; Kris Chadee; Stefan J Urbanski; Deirdre Church; Paul L Beck
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

Review 2.  Laboratory Diagnosis of Parasites from the Gastrointestinal Tract.

Authors:  Lynne S Garcia; Michael Arrowood; Evelyne Kokoskin; Graeme P Paltridge; Dylan R Pillai; Gary W Procop; Norbert Ryan; Robyn Y Shimizu; Govinda Visvesvara
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

Review 3.  Colonoscopic diagnosis of amebiasis: a case series and systematic review.

Authors:  Ko-Chao Lee; Chien-Chang Lu; Wan-Hsiang Hu; Shung-Eing Lin; Hong-Hwa Chen
Journal:  Int J Colorectal Dis       Date:  2014-10-28       Impact factor: 2.571

4.  [Protozoa and protozoan infections of humans in Central Europe].

Authors:  Julia Walochnik; Horst Aspöck
Journal:  Wien Med Wochenschr       Date:  2014-10-23

5.  Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals.

Authors:  Koji Watanabe; Naoyoshi Nagata; Katsunori Sekine; Kazuhiro Watanabe; Toru Igari; Junko Tanuma; Yoshimi Kikuchi; Shinichi Oka; Hiroyuki Gatanaga
Journal:  Am J Trop Med Hyg       Date:  2014-07-21       Impact factor: 2.345

6.  Comparison of Various Methods in the Diagnosis of Entamoeba histolytica in Stool and Serum Specimens.

Authors:  Hakan Uslu; Osman Aktas; Muhammet Hamidullah Uyanik
Journal:  Eurasian J Med       Date:  2016-06

7.  Epidemiology of Domestically Acquired Amebiasis in Japan, 2000-2013.

Authors:  Masahiro Ishikane; Yuzo Arima; Atsuhiro Kanayama; Takuri Takahashi; Takuya Yamagishi; Yuichiro Yahata; Tamano Matsui; Tomimasa Sunagawa; Tomoyoshi Nozaki; Kazunori Oishi
Journal:  Am J Trop Med Hyg       Date:  2016-03-14       Impact factor: 2.345

8.  Risk factors for intestinal parasitic infections in preschoolers in a low socio-economic area, Diamantina, Brazil.

Authors:  Luciana N Nobre; Renata V Silva; Mariana S Macedo; Romero A Teixeira; Joel A Lamounier; Sylvia C C Franceschini
Journal:  Pathog Glob Health       Date:  2013-03       Impact factor: 2.894

9.  Multiple simultaneous infections in a patient with well-controlled HIV: when Occam's razor fails.

Authors:  Miranda Sherley; Sarah Jane Martin
Journal:  BMJ Case Rep       Date:  2017-12-01

Review 10.  Regulation of virulence of Entamoeba histolytica.

Authors:  Chelsea Marie; William A Petri
Journal:  Annu Rev Microbiol       Date:  2014-06-16       Impact factor: 15.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.